Overactive Bladder
Potential Role of Monocyte Chemoattractant Protein-1 in Monitoring Disease Progression and Response to Treatment in Overactive Bladder Patients.
January 10, 2021
Clinical Manifestations of Overactive Bladder With Migraine as a Comorbidity: A Prospective Cross-Sectional Study.
January 10, 2021
Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.
January 10, 2021
GEMTESA® (vibegron) Receives U.S. FDA Approval for the Treatment of Patients with Overactive Bladder (OAB)
January 4, 2021
Adverse Childhood Experiences in Women With Overactive Bladder or Interstitial Cystitis/Bladder Pain Syndrome.
January 3, 2021
The Effect of Social Determinants of Health on Overactive Bladder Symptom Severity.
December 27, 2020
[Follow-up and evaluation of non-neurogenic OAB treatments].
December 27, 2020
The impact of overactive bladder on health-related quality of life in Korea: based on the results of a Korean Community Health Survey.
December 27, 2020
Do Older Adults with Overactive Bladder Demonstrate Impaired Executive Function Compared to Their Peers Without OAB?
December 20, 2020
Vibegron Improves Quality-of-Life Measures in Patients With Overactive Bladder: Patient-Reported Outcomes From the EMPOWUR Study.
December 20, 2020
Evaluating the Quality of Overactive Bladder Patient Education Material on YouTube: A Pilot Study Using the Patient Education Materials Assessment Tool.
December 13, 2020
Which Drugs Are Best for Overactive Bladder? From Patients' Expectations to Physicians' Decisions.
December 6, 2020
Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity.
December 6, 2020
Mirabegron Add-On Therapy to Tamsulosin in Men with Overactive Bladder: Post Hoc Analyses of Efficacy from the MATCH Study.
November 29, 2020
[First-line treatment for non-neurogenic overactive bladder].
November 29, 2020